News Heart hope for Heartseed/Novo Nordisk HS-001 cell therapy Heartseed & Novo Nordisk say a patient has been successfully dosed with cell therapy HS-001.
News Novo Nordisk crowns cell therapy pipeline with $598m Heartse... Novo Nordisk is paying $55 million upfront to secure rights to a cell therapy for heart failure developed by Japanese startup Heartseed.
News UK Knowledge Quarter welcomes Boehringer Ingelheim AI accele... Boehringer Ingelheim has announced expansion of its global Computational Innovation footprint with a new centre dedicated to AI & ML in the UK.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
